Trial
NCT04955743
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Yale University
Collaborators
Merck Sharp & Dohme LLC
Condition
Melanoma
Intervention
Pembrolizumab
Why stopped
Lack of activity in the drugs
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-04